The Innovative Licensing and Access Pathway (ILAP) is focused on getting the most transformative new medicines to patients in the UK health system more quickly.
Similar Posts
Access, new active substance and biosimilar work sharing initiatives
Information on applying for New Active Substance Work Sharing Initiative (NASWSI) and Biosimilar Work Sharing Initiative (BSWSI) assessments and list of approved products.
Decision: Advertising Investigations: July 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Concizumab approved to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with haemophilia A or B with inhibitors
As with any medicine, the MHRA will keep the safety and effectiveness of concizumab under close review.
Blood: authorisations and safety reporting
Information about ensuring blood and blood component safety.
Clinical trials: Non-investigational medicinal products
Guidance on using non-investigational medicinal products in a clinical trial.
Professor Henrietta Hughes: Putting Patient Safety at the Heart of Regulatory Innovation
Professor Henrietta Hughes reflects on how MHRA strategy must prioritise patient safety via listening to lived experiences, fostering collaboration & innovation.